Partners Aim To Make Oncology Biosimilars | Chemical & Engineering News
Volume 90 Issue 24 | p. 17 | Concentrates
Issue Date: June 11, 2012

Partners Aim To Make Oncology Biosimilars

Department: Business
Keywords: biosimilars, generic drugs, pharmaceuticals, oncology, monoclonal antibodies

Dr. Reddy’s Laboratories, in India, and Merck Serono, a division of Germany’s Merck KGaA, will jointly develop generic biologic, or biosimilar, drugs. They will focus primarily on developing, manufacturing, and selling monoclonal antibodies for oncology purposes. The partners will share R&D costs and divide up worldwide commercial activities. Dr. Reddy’s will handle early product development, including Phase I clinical trials. After that, Merck Serono will assume manufacturing and development through Phase III.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment